BRCA1在乳腺癌中的表达及与多西紫杉醇疗效的关系  

Relation between breast cancer susceptibility gene 1 expression and the efficacy of docetaxel in breast cancer

作　　者：鲁凯[1] 刘燕文[2] 李惠[4] 刘东[1] 叶红玲[3] 徐良[1] 刘苏[1] Lu kai Liu Yanwen Li Hui Liu Dong Ye Hongling Xu Liang Liu Su(Department of General Surgery, the Second Hospital of Lianyungang, Lianyungang 222032, Chin)

机构地区：[1]连云港市第二人民医院甲状腺乳腺外科,222023 [2]连云港市第二人民医院肿瘤内科,222023 [3]连云港市第二人民医院检验科,222023 [4]江苏省中医院病理科,南京210029

出　　处：《中华内分泌外科杂志》2016年第5期382-385,共4页Chinese Journal of Endocrine Surgery

基　　金：连云港市科技局社会发展计划（SH1333）

摘　　要：目的研究人类乳腺癌易感基因BRCA1在乳腺癌中的表达及与多西紫杉醇疗效的关系。方法应用实时定量荧光PCR（RT—QPCR）技术检测100例乳腺癌组织中BRCA1的表达，TAC方案对其行新辅助化疗，研究BRCA1与多西紫杉醇疗效的关系。结果BRCA1基因表达与年龄、淋巴结转移、临床分期无明显相关性，与组织学分级呈正相关，与HER2的表达呈负相关。新辅助化疗有效组中．BRCA1高表达的比例为53．1％（52／98），低表达的比例为46．9％（46／98），BRCA1高表达的乳腺癌患者对紫杉类药物敏感性高，低表达者对紫杉类药物敏感性低。结论BRCAl高表达的患者可从紫衫类药物获益，BRCAl可作为乳腺癌化疗的分子预测指标之一。Objective To study the expression of breast cancer susceptibility gene 1 （BRCA1） in breast cancer tissues and its relation with docetaxel sensitivity. Methods BRCA1 expression was measured by RT- QPCR. The docetaxel based （TAC regimen） new adjuvant chemotherapy was given to breast cancer patients. Re- suit The expression of BRCA1 had no relationship with age, lymphnode metastasis or clinical stage. It had a positive correlation with histology grade, and had a negative correlation with Her-2 expression. In patients with effective response after new adjuvant chemotherapy, the expression rate of BRCA1 was 53.1% and the negative rate was 46.9%. The BRCA1 positive patients were more sensitive to docetaxel chemotherapy regimen compared to BRCA1 negative patients. Conclusions Breast cancer patients with highly expressed BRCA1 can benefit from docetaxel chemotherapy regimen. BRCA1 can be used as a molecule marker for predicting efficacy of chemother- apy for breast cancer patients.

关 键 词：乳腺癌 BRCA1基因 荧光实时定量PCR 多西紫杉醇 

分 类 号：R737.9[医药卫生—肿瘤]